News Release

February 17, 2022
Akira Sasa, Representative Director EPS Corporation
Kenji Sakuma, Representative Director EP-CRSU Co., Ltd.
Akira Sasa, Representative Director EP Croit Co., Ltd.

Announcement on Reorganization of CRO Business
EPS Corporation, EP-CRSU Co., Ltd., and EP Croit Co., Ltd. are pleased to announce that the threecompanies will absorb and merge, and integrate their businesses. EPS Corporation will be the surviving
company.

１． Purpose of the Reorganization
This restructuring, one of the initiatives of “New EPS”, follows a management buyout (MBO) that wascompleted last year, when the EPS Group celebrated its 30th anniversary.
The three companies to be restructured have been developing their businesses while taking advantage
of each company's unique characteristics and have thus established their respective businessfoundations. However, the business environment surrounding CROs has recently undergone majorchanges.
In the field of real-world evidence, utilization of daily clinical data such as receipts, electronic medical
records, PHRs (Personal Health Records) and patient registries are expanding, in addition to postmarketing surveillance and pharmacovigilance as an extension of drug development. In the field ofclinical trials, the widespread use of DCTs (Decentralized Clinical Trials) is beginning to become a reality
in Japan on the back of the COVID-19 pandemic. Furthermore, the use of patient registry data as control
arm data for clinical trials is now at the practical stage, and the barriers between clinical and real-world
trials are expected to become lower in the future.
On the other hand, under the healthcare policy in Japan, the importance of measures regarding presymptomatic illnesses and disease prevention is increasing along with the progress of treatments, due tothe backdrop of the continual increase in national health care costs. As such, there is an increase inopportunities for business such as cooperating with local governments to encourage medical checkups.
In addressing the above-mentioned issues, one constant is the need for new technologies such as ICTand AI. The purpose of this reorganization is to promote the creation of solutions that meet the needs ofthe new era by bringing together the experience and knowledge dispersed among the three EPS Groupbranches: EPS Corporation, which focuses on clinical development support services, EP-CRSU Co., Ltd.,
which focuses on services for academia, and EP Croit Co., Ltd., which has solid IT technology.
Now, after the MBO, the EPS Group will rekindle the spirit and vitality of its founding and contributeto the further development of the health industry by boldly challenging new fields.

News Release

２．Effective Date of the Reorganization (Tentative)（1）Absorption-Type Merger of EP-CRSU Co., Ltd. by EPS Corporation
Friday, April 1, 2022
（2）Absorption-Type Merger of EP Croit Co., Ltd. by EPS Corporation
Friday, July 1, 2022
３．Outline of the Company Structure Post-reorganization
Surviving Company

Dissolving Company

Dissolving Company

Name

EPS Corporation

EP-CRSU Co., Ltd.

EP Croit Co., Ltd.

Location of

2-23 Shimomiyabicho,

6-29 Shin-ogawamachi,

6-29 Shin-ogawamachi,

head office

Shinjuku-ku, Tokyo, Japan

Shinjuku-ku, Tokyo, Japan

Shinjuku-ku, Tokyo, Japan

Representative

Akira Sasa,

Kenji Sakuma,

Akira Sasa,

Representative Director

Representative Director

Representative Director

Clinical Development, Post

Clinical Research,

Clinical Development, Post

Marketing Surveillance

Investigator-initiatedMarketing Surveillance

and Pharmacovigilance

Clinical Trials and Patientand PharmacovigilanceBusinessRegistry
Employees*

2,328388557

Capital

100 million yen

100 million yen

90 million yen

Principal

EPS Holdings, Inc. (100%)

EPS Holdings, Inc. (100%)

EPS Corporation (100%)

Shareholder*January 2022

For Inquiries
Public Relations Officer, General Affairs Office, Management Center, EPS Corporation
E-mail: prj-epskoho@eps.co.jp